Opendata, web and dolomites

Gri3D

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Gri3D project word cloud

Explore the words cloud of the Gri3D project. It provides you a very rough idea of what is the project "Gri3D" about.

customers    company    validate    dish    standard    producing    move    initiate    automated    endless    opened    economical    volume    stem    handling    customer    manufacturing    organoids    precision    spin    generate    off    line    biocompatible    clinical    capacity    2016    hydrogel    expand    world    revenues    epfl    first    termed    market    diagnostics    practical    gt    single    groups    sa    3d    cells    microembossing    organoid    annual    founded    hydra    basic    feasibility    sme    bioscience    auomates    medicine    recurrent    2m    base    total    health    pharmaceutical    leader    cumulative    corresponds    assays    units    machine    2021    switzerland    tenth    patient    liquid    instrument    successful    run    industry    academic    models    business    strategy    verify    entry    gri3d    commercializing    possibilities    sun    clients    microstructured    tested    maximum    translated    viability    ambition    organ    miniature    introduction    prototypes    technologies    industrial    care    mechanism    intention    platform    600m    cultures   

Project "Gri3D" data sheet

The following table provides information about the project.

Coordinator
SUN BIOSCIENCE SA 

Organization address
address: EPFL INNOVATION PARK BATIMENT C
city: LAUSANNE
postcode: 1015
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://www.sunbioscience.ch
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SUN BIOSCIENCE SA CH (LAUSANNE) coordinator 50˙000.00

Map

 Project objective

The ability to generate miniature organ models in a dish, termed organoids, from patient stem cells has opened endless possibilities for applications in precision medicine. SUN bioscience SA, a spin-off company of EPFL in Switzerland, was founded in 2016 with the ambition to move these organoid cultures from basic research to the Health Care industry.

To reach this goal, SUN bioscience has developed Gri3D, a microstructured biocompatible hydrogel platform, and aims to establish this technology as a new standard for growing organoids at industrial scale and precision. Gri3D prototypes have been field tested with over 30 European academic and pharmaceutical R&D groups. In addition, SUN bioscience has developed an industrial automated manufacturing mechanism for Gri3D that is now being translated into the world-wide first machine, Hydra I, that auomates liquid handling with hydrogel microembossing.

The objective of this feasibility study is to verify the technical, economical and practical viability of Gri3D and to ensure its successful market entry in Europe. Specifically, the first step is to validate the production capacity of Hydra I by producing 1’000 Gri3D units, which corresponds to one tenth of the total annual target production volume. In a second step, SUN bioscience aims to validate the market by commercializing these 1’000 Gri3D units to existing customers and to expand its customer base to a total of 20-40 recurrent clients.

According to our current strategy, SUN bioscience will run at maximum single line production capacity with cumulative revenues of >€2M within 3 years after market introduction of Gri3D. The 3D technologies market is expected to reach €600M by 2021. The long-term business objective is to implement organoid assays on Gri3D and to establish SUN bioscience as a leader in clinical diagnostics with the intention to initiate a phase 2 SME instrument project along this path.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GRI3D" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GRI3D" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

SHN (2017)

Universal Smart Hypodermic Needle for preventing reuse and accidental pricks

Read More  

NAS (2018)

Nexilis augmentation system

Read More